Several studies worldwide have demonstrated variable sensitivities ranging from 75-95.2% for TLE1 as an immunomarker for SS, with two of them concluding it to be more sensitive for the poorly differentiated subtype [2,3,13,18]. This evidence concerns the gene TLE1 and synovial sarcoma.